PreveCeutical Medical Inc. Stock price Deutsche Boerse AG

Equities

18H

CA74141E1043

Pharmaceuticals

Delayed Deutsche Boerse AG 03:00:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.014 EUR -3.45% Intraday chart for PreveCeutical Medical Inc. -6.67% 0.00%

Financials

Sales 2021 - Sales 2022 - Capitalization 13.38M 9.85M 9.13M
Net income 2021 -1M -736K -682K Net income 2022 -1M -736K -682K EV / Sales 2021 -
Net Debt 2021 2.91M 2.14M 1.99M Net Debt 2022 3.29M 2.42M 2.24M EV / Sales 2022 -
P/E ratio 2021
-7.36 x
P/E ratio 2022
-8.81 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 75.91%
More Fundamentals * Assessed data
Dynamic Chart
PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program CI
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program MT
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PreveCeutical & Endosane Announce Update on Intranasal CBD Application MT
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application CI
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PrevCeutical Medical Provides Update MT
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia CI
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof CI
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PreveCeutical Medical Inc. Auditor Raises 'Going Concern' Doubt CI
PreveCeutical Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PreveCeutical Medical Inc. Appoints Shawn Sadler as Head of Artificial Intelligence CI
More news
1 day-3.45%
1 week-6.67%
6 months-6.67%
More quotes
1 week
0.01
Extreme 0.014
0.02
1 month
0.01
Extreme 0.014
0.02
Current year
0.01
Extreme 0.014
0.02
1 year
0.01
Extreme 0.014
0.03
3 years
0.00
Extreme 0.004
0.03
5 years
0.00
Extreme 0.0001
0.08
10 years
0.00
Extreme 0.0001
0.16
More quotes
Managers TitleAgeSince
Founder - 14-12-14
Chief Executive Officer - 14-12-14
Founder - 14-12-14
Members of the board TitleAgeSince
Director/Board Member 64 23-02-16
Founder 73 14-12-14
Chief Executive Officer - 14-12-14
More insiders
Date Price Change
24-03-28 0.014 -3.45%
24-03-27 0.0145 +3.57%
24-03-26 0.014 -6.67%
24-03-25 0.015 0.00%
24-03-22 0.015 0.00%

Delayed Quote Deutsche Boerse AG, March 28, 2024 at 03:00 am EDT

More quotes
PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.
More about the company
  1. Stock
  2. Equities
  3. Stock PreveCeutical Medical Inc.
  4. Stock PreveCeutical Medical Inc. - Deutsche Boerse AG